Depo Provera. Position paper on clinical use, effectiveness and side effects

Journal of Family Planning and Reproductive Health Care

Volumn 25, Issue 2, 1999, Pages 69-76

  Bigrigg, Alison ^a   Evans, Margaret ^a   Gbolade, Babatunde ^a   Newton, John ^a   Pollard, Louise ^a   Szarewski, Anne ^a   Thomas, Celia ^a   Walling, Martyn ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; ESTROGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

AFFECTIVE NEUROSIS; AMENORRHEA; ARTICLE; BLOOD PRESSURE; BONE DEMINERALIZATION; BONE MINERAL; BREAST CANCER; COMPARATIVE STUDY; CONTRACEPTION; DRUG EFFICACY; FAMILY PLANNING; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIFESTYLE; LOW BIRTH WEIGHT; MEMORY; MENSTRUAL CYCLE; MENSTRUATION DISORDER; ORAL DRUG ADMINISTRATION; PATIENT COUNSELING; SEXUAL INTERCOURSE; THROMBOSIS; WEIGHT GAIN;

AMERICAS; CLINICAL RESEARCH; CLINICAL TRIALS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS, PROGESTIN--SIDE EFFECTS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; CONTRACEPTIVE EFFECTIVENESS; CONTRACEPTIVE METHODS--SIDE EFFECTS; DEPO-PROVERA--SIDE EFFECTS; DEVELOPED COUNTRIES; FAMILY PLANNING; INJECTABLES--SIDE EFFECTS; LITERATURE REVIEW; MEDROXYPROGESTERONE ACETATE--SIDE EFFECTS; NORTH AMERICA; NORTHERN AMERICA; RESEARCH METHODOLOGY; UNITED STATES;

ADOLESCENT; ADULT; CLINICAL TRIALS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED;

EID: 0032799056     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Luscombe H. The relevance of migraine to contraceptive use. Br J Family Planning 1992; 18: 18-19.
2. Belsey M. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Advances in Contraception 1991; 7: 257-270.
3. Robinson W, Broome M. Depo-provera for PMT. Br J Family Planning 1992; 18: 28.
4. Cooper E. Depo Provera for PMT. Br J Family Planning 1992; 18: 97.
5. De Eulaer K, Gruber C, Hayes R, et al. Medroxyprogesterone acetate and homozygous sickle cell disease. Lancet 1982; ii: 229-231.
6. Gray R H. Reduced risk of pelvic inflammatory disease with injectable contraceptive. Lancet 1985; 1: 1046.
7. Hull V. The effect of hormonal contraceptive on lactation: current findings, methodological considerations and future priorities. Studies in Family Planning 1981; 12: 134-163.
8. WHO Task Force on Oral Contraceptives, Special Programme of Research, Development and Research Training in Human Reproduction: effects of hormonal contraceptive on breast milk composition and infant growth. Studies in Family Planning 1988; 19: 461-469.
9. Schwallie P C. The effect of DMPA on the fetus and nursing infant: a review. Contraception 1931; 23: 375-386.
10. Koetsawang S. Injected long-acting medroxyprogesterone acetate effect on human lactation and concentrations in milk. J Med Assoc Thai 1977; 60: 57-60.
11. Schwallie P C, Assenzo J R. The effect of DPMA on pituitary and ovarian function, and the return to fertility. Contraception 1974; 10: 181-202.
12. FPA leaflet on injectables, 1997.
13. Depo Provera product characteristics. Pharmacia & Upjohn, 1997.
14. Garza-Flores J, Carlenas S, Rodrigues V. Return to ovulation following the use of long-acting injectable contraception, a comparative study. Contraception 1985; 31: 361-366.
15. Mishell D R Jr, El-Habashy M A, Good R G, et al. Contraception with an injectable progestin: a study of its use in post partum women. Am J Obstet Gynecol 1968; 101: 1046-1053.
16. WHO/NRC. Breast feeding and Fertility Regulation: current knowledge and programme policy implications. WHO Bulletin 1983; 61: 371-382.
17. WHO Task Force on Long-Acting Agents for Fertility Regulation: Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone oenanthate given in 2 dosage regimens and depot-medroxyprogesterone acetate. A final report. Contraception 1983; 28: 1-20.
18. WHO Task Force on Long-Acting Systemic Agents for Fertility Regulation: A multicentral Phase III comparative Clinical trial of Depo Medroxyprogesterone acetate given at 3 monthly does of 100 mg or 150 mg. Contraception 1986; 34: 223-235.
19. Veasey M P, Lawless M, Yeates D, et al. Progestogen only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Family Planning 1992; 10: 117-121.
20. Petterson et al. CREST Study of Failed Sterilisation. 1996.
21. Schmidt F, Sivin I, Waldman S. The Copper T 380 IUD. Proceedings from the 4th International Conference on IUDs 1995; 298-307.
22. Rowe P J. Clinical Performance of Copper IUDs. Proceedings from the 4th International Conference on IUDs 1995; 13-31.
23. Vessey M P, Lawless M, Yeates D, et al. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Family Planning 1985; 10: 117-121.
24. Belsey E M, Pinol E P, et al. Menstrual bleeding patterns in untreated women. Contraception 1997; 55: 57-65.
25. Belsey E M, Peregoudor S, et al. Determinants of menstrual bleeding patterns among women using natural and hormonal methods of contraception: regional variations. Contraception 1988; 38: 227-242.
26. WHO Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction. A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. Contraception 1987; 35: 591-610.
27. Belsey E M and Task Force on Long-Acting Systemic Agents for Fertility Regulation. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception. Advances in Contraception 1991; 7: 257-270.
28. Machin D, Farley T M, Burca B, et al. Assessing changes in vaginal bleeding patterns in contracepting women. Contraception 1988; 38: 165-179.
29. Said S, Sadek W, Rocca W, et al. Clincal evaluation of therapeutic effectiveness of ethyloestradiol and oestrone sulphate on prolonged bleeding in women using DMPA. WHO Task Force on Long-Acting Systemic Agents. Human Reproduction 1996; 11: 1-13.
30. Amatayakul K, Siarasonboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone users. Contraception 1980; 22: 605-622.
31. Westhoff C, Weiland D, Tiezzi L. Depression in users of depo-medroxyprogesterone acetate. Contraception 1995; 51: 351-354.
32. Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reproductive Med 1996; 41: 401-405.
33. Kremer J, de Bruijn H M, Hindriks F R. Serum high density lipoprotein cholesterol levels in women using a contraceptive injection of depto-medroxyprogesterone acetate. Contraception 1980; 22: 359-367.
34. Deslypere J F, Thiery M, Vermeulen A. Effect of long-term hormonal contraception on plasma lipids. Contraception 1985; 31: 633-642.
35. Fahmy K, Khairy M, Allam G, et al. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991; 44: 431-444.
36. Enk, L, Lundgren B M, Lindberg U B, et al. A prospective, one year study on the effects of two long acting injectable contraceptives (depot medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Horm Metab Res 1992; 24: 85-89.
37. Godsland I F, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. New Eng J Med 1990; 323: 1375-1381.
38. Fotherby K. Update on lipid metabolism and oral contraception. Br J Family Planning 1990; 15: 23-26.
39. Black H R, Leppert P, DeCherney A. The effect of medroxyprogesterone acetate on blood pressure. Int J Gynaecol-Obstet 1978; 17: 83-87.
40. Schwallie P C, Assenzo J R. Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973; 24: 331-339.
41. Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. Br Med J 1991; 303: 13-16.
42. Cundy T, Reid I R, Roberts H. DMPA and Bone Density: Authors Reply. Br Med J 1991; 303: 468.
43. Cundy T, Cornish J, Evans M C, et al. Recovery of bone density in women who stop using medroxyprogesterone acetate. Br Med J 1994; 308: 247-249.
44. Cromer B A, Blair J M, Mahan J D, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo Provera), levonorgestrel (Norplant) or oral contraceptives. J Paediat 1996; 129: 671-676.
45. Virutamasen P, Wangsuphachast S, Reinprayoon D, et al. Trabecular bone in long term depot-medroxyprogesterone acetate users. Asia-Oceania J Obstet Gynaecol 1994; 20: 269-274.
46. Adachi J D, Sargeant E J, Sgle M A, et al. A double blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy. Br J Obstet Gynaecol 1977; 104: 640-70.
47. Gbolade B, Ellis S, Murby B, et al. Bone density in long term users of DMPA. Br J Obstet Gynaecol 1998; 105: 790-794.
48. Riggs B C, Wahner H W, Seeman E, et al. Changes in bone density of the proscenial femur with aging. J Clin Invest 1982; 70: 716-723.
49. Pardthaisong T, Gray R H. In utero exposure to steroid contraceptives and outcome of pregnancy. Am J Epidemiol 1991; 134: 795-803.
50. Gray R H, Pardthaisong T. In utero exposure to steroid contraceptives and survival during infancy. Am J Epidemiol 1991; 134: 804-811.
51. Hogue C J. Invited commentary: the contraceptive tightrope. Am J Epidemiol 1991; 134: 812-815.
52. Pardthaisong T, Gray R H. Steroid contraceptive use and pregnancy outcome. Teratology 1988; 38: 51-58.
53. Altman D G, Hytten F E. Intrauterine growth retardation: let's be clear about it. Br J Obstet Gynecol 1989; 96: 1127-1132.
54. Yovich J L, Wilcox D L, Wilkinson S P, et al Medroxyprogesterone acetate does not perturb the profile of steroid metabolites in urine during pregnancy. J Endocrinol 1985; 104: 453-459.
55. Katz Z, Lancet M, Skornik J, et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynaecol 1985; 65: 775-780.
56. Jaffe B, Harlap S, Baras M, et al. Long-term effects of MPA on human progeny: intellectual development. Contraception 1988; 37: 607-619.
57. Jaffe B, Shye D, Harlap S, et al. Aggession, physical activity levels and sex role identity in teenagers exposed in utero to MPA. Contraception 1989; 40: 351-363.
58. Jaffe B, Shye D, Harlap S, et al. Health, growth and sexual development of teenagers exposed in utero to medroxyprogesterone acetate. Paediat Perinatal Epidemiol 1990; 4: 184-195.
59. Pardthaisong T, Gray R H. 1992
60. OPCS Series DH3 no 24. Mortality statistics (England and Wales). Perinatal and infant social and biological factors. 1990, xiii.
61. Pardthaisong T. Return of fertility after use of the injectable contraceptive Depo Provera: updated data analysis. J Biosocial Science 1984; 16: 23-34.
62. McDaniel E B, Pardthaisong T. Return of menstruation and fertility in Thai women after contraceptive injections. J Biosocial Science 1971; 3: 209-222.
63. Koetsawant S, Srisuphandit S, Srivanaboon S, et al. Intramuscular depomedroxyprogesterone acetate for contraception. J Med Assoc Thai 1974; 57: 396-406.
64. Zanartu J. Long term contraceptive effect of injectable progestogens. Inhibition and reestablishment of fertility. Int J Fert 1968; 12: 415-426.
65. Mishell D R Jr, Thorneycroft I H, Kharma K M, et al. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol 1972; 113: 372-376.
66. Ortiz A, Hiroi M, Stanezyk Z. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 1977; 44: 32-38.
67. Jeppsson, et al. Plasma levels of medroxyprogesterone acetate (MPA), sex hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo Provera) as a contraceptive agent. Acta Endocrinologica 1982; 99: 339-343.
68. The WHO Collaborative study of neoplasia and steroid contraceptives. Depo medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 1991; 49: 186-190.
69. Stanford I L, Brinton L A, Berman M I, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 1993; 54: 243-248.